Exploring the Potential of Low-Dose Naltrexone in the Management of Pediatric Acute-Onset Neuropsychiatric Syndrome - LDN PANS

LDN for treating PANS

Introduction

Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) is a complex and often debilitating condition characterized by the sudden onset of obsessive-compulsive disorder (OCD), severe food restrictions, and a range of neuropsychiatric symptoms in children and adolescents. Subsets of PANS, such as Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), are linked to postinfectious autoimmune or inflammatory processes, complicating both diagnosis and treatment.

Emerging therapies like low-dose naltrexone (LDN) are gaining attention for their potential immunomodulatory effects. This article provides an overview of PANS, its pathophysiology, standard management strategies, and the evolving role of LDN as an adjunctive therapy.

Understanding Pediatric Acute-Onset Neuropsychiatric Syndrome

PANS is clinically defined by a rapid onset—often within 24 to 72 hours—of OCD or severe food restriction, accompanied by at least two additional neuropsychiatric symptoms. These can include anxiety, irritability, aggression, emotional lability, cognitive decline, sensory or motor abnormalities, and somatic complaints such as sleep disturbances or urinary frequency. Symptoms typically present in prepubertal children, averaging around 7 years of age, but can occur across a broader pediatric range. Unlike chronic OCD or tic disorders, PANS often follows a relapsing-remitting course triggered by infections.

PANDAS, a well-studied subset, is specifically associated with group A streptococcal infections. Molecular mimicry between streptococcal antigens and basal ganglia proteins may trigger an autoimmune response. Broader PANS cases involve diverse pathogens, including influenza, varicella, Mycoplasma pneumoniae, and Borrelia burgdorferi (Lyme disease). Diagnosis relies on clinical history and exclusion of other conditions like Sydenham’s chorea or autoimmune encephalitis. Consensus guidelines from the American Academy of Pediatrics recommend a multidisciplinary evaluation involving pediatrics, psychiatry, immunology, and infectious disease specialists.

Pathophysiology of PANS

PANS is primarily driven by neuroinflammation and autoimmunity targeting the basal ganglia, a brain region involved in motor control, habit formation, and emotional regulation. Postinfectious immune activation leads to cytokine release and production of antineuronal antibodies, which can disrupt normal neural signaling. Elevated proinflammatory markers, such as interleukin-6 and tumor necrosis factor-alpha, often correlate with symptom severity. Neuroimaging studies reveal microstructural basal ganglia changes, and cerebrospinal fluid analyses occasionally show intrathecal inflammation.

Genetic susceptibility and environmental triggers may increase risk, but the episodic nature of PANS suggests dynamic interactions between persistent immune activation and reinfection, emphasizing the need for interventions addressing both infectious and inflammatory mechanisms.

Standard Treatment Approaches

Management of PANS involves a tiered approach focusing on symptom relief, infection control, and immunomodulation:

• Psychiatric interventions: Cognitive-behavioral therapy (CBT) for OCD, exposure-response prevention, and low-dose selective serotonin reuptake inhibitors (SSRIs) for acute anxiety and compulsions.

• Antimicrobial therapy: Antibiotics such as penicillin or azithromycin are used for PANDAS to reduce relapse rates.

• Immunomodulation: NSAIDs for mild inflammation, corticosteroids for acute flares, and intravenous immunoglobulin (IVIG) or plasma exchange for severe, refractory cases. Response rates for IVIG and plasma exchange can exceed 60%, though accessibility and side effects limit widespread use.

Despite these strategies, up to 30% of patients remain treatment-resistant, prompting exploration of novel therapies like LDN.

Low-Dose Naltrexone: Mechanism and Applications

Low-dose naltrexone (LDN) involves administering naltrexone at 0.5–4.5 mg daily—far below standard doses used for opioid or alcohol dependence. At these low doses, LDN transiently blocks mu-opioid receptors, inducing a rebound increase in endogenous opioids such as beta-endorphins, which have analgesic and immunomodulatory effects.

LDN also inhibits Toll-like receptor 4 (TLR4) on microglia, reducing proinflammatory cytokine production and central neuroinflammation. Evidence supports its use in conditions like fibromyalgia, multiple sclerosis, and Crohn’s disease, where it helps modulate immune responses and reduce symptoms with minimal side effects. Pediatric applications are emerging, with compounded formulations allowing precise dosing.

LDN in PANS: Emerging Evidence

LDN’s anti-inflammatory properties make it a promising adjunct for PANS, especially in cases where standard therapies do not fully resolve neuroinflammation. Early clinical observations suggest:

• Doses of 0.5–3 mg nightly can help reduce flare severity without causing sleep disruption.

• Retrospective analyses in pediatric chronic pain cohorts indicate improved functional outcomes and reduced symptom burden.

• Mechanistically, LDN may suppress microglial TLR4 signaling, mitigating basal ganglia inflammation.

• Case series in dysautonomia and complex regional pain syndrome report improved autonomic and inflammatory symptoms with LDN use.

While these findings are encouraging, they remain anecdotal or observational. No randomized controlled trials have been conducted specifically in PANS, highlighting the need for rigorous research to establish optimal dosing, efficacy, and long-term safety.

Conclusion

PANS sits at the intersection of infection, immunity, and neuropsychiatry, requiring a nuanced, multimodal treatment approach. Standard therapies—including antimicrobials, psychotropics, and immunomodulators—form the foundation of care, but adjunctive treatments like LDN offer a low-risk option to target residual neuroinflammation.

Preliminary evidence suggests LDN may improve quality of life for affected children, but clinicians should proceed cautiously, compounding doses for pediatric precision and advocating for collaborative clinical trials. Advancing PANS care will depend on interdisciplinary vigilance and continued research, transforming this challenging syndrome into a manageable condition.

Dr. Yoon Hang Kim is a distinguished physician, expert in Low Dose Naltrexone (LDN) therapy, and a published author dedicated to advancing integrative medicine. With a deep commitment to patient-centered care, Dr. Kim combines his extensive medical expertise with innovative approaches to help individuals achieve optimal health and wellness. His work in LDN therapy has positioned him as a trusted authority in the field, and his published writings reflect his passion for empowering patients and healthcare professionals alike. To learn more about Dr. Kim's work and insights, visit yoonhangkim.com.

References

• American Academy of Pediatrics. (2025). Pediatric acute-onset neuropsychiatric syndrome (PANS): Clinical report. Pediatrics, 155(3), Article e2024070334. https://doi.org/10.1542/peds.2024-070334

• Chang, K., Frankovich, J., Cooperstock, M., et al. (2015). Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): Recommendations from the 2013 PANS Consensus Conference. Journal of Child and Adolescent Psychopharmacology, 25(1), 3–13. https://doi.org/10.1089/cap.2014.0084

• Frankovich, J., Thienemann, M., Pearlstein, J., et al. (2015). Multidisciplinary clinic dedicated to treating youth with PANS: Presenting characteristics of the first 47 consecutive patients. Journal of Child and Adolescent Psychopharmacology, 25(1), 38–47. https://doi.org/10.1089/cap.2014.0060

• Li, Z., You, Y., Griffin, N., et al. (2018). Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. International Immunopharmacology, 61, 178–184. https://doi.org/10.1016/j.intimp.2018.05.024

• Pfeiffer, H. C. V., Wickstrom, R., Skov, L., et al. (2020). Clinical guidance for suspected PANS in Nordic countries. Nordic Journal of Psychiatry, 74(8), 527–534. https://doi.org/10.1080/08039488.2020.1759821

• Swedo, S. E., Frankovich, J., & Murphy, T. K. (2017). Overview of treatment of pediatric acute-onset neuropsychiatric syndrome. Journal of Child and Adolescent Psychopharmacology, 27(7), 562–574. https://doi.org/10.1089/cap.2017.0073

• Swedo, S. E., Leckman, J. F., & Rose, N. R. (2012). Modifying the PANDAS criteria to describe PANS. Pediatric Therapeutics, 2(2), 1000113. https://doi.org/10.4172/2167-7662.1000113

• Thienemann, M., Murphy, T. K., Leckman, J., et al. (2017). Clinical management of PANS: Part I—Psychiatric and behavioral interventions. Journal of Child and Adolescent Psychopharmacology, 27(7), 566–573. https://doi.org/10.1089/cap.2016.0145

• Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451–459. https://doi.org/10.1007/s10067-014-2517-2